Dr. Gregory P. Kalemkerian – Mesothelioma Doctor – Co-Director of the Thoracic Oncology Program

Share This:

University of Michigan Health System

Med Inn Building

1500 East Medical Center Drive, Room C350

Ann Arbor, Michigan 48109

Phone: 734.936.5281

Fax: 734.647.8792

Email Address: kalemker@umich.edu

Dr. Gregory P. Kalemkerian is Co-Director of the Thoracic Oncology Program, Department of Internal Medicine, at the University of Michigan Health System. Dr. Kalemkerian is also Clinical Associate Professor in the Department of Internal Medicine as well as Cancer Center Member. In addition to mesothelioma, Dr. Kalemkerian’s clinical interests include lung cancer and thymoma. His research interest is in experimental therapeutics.

Dr. Kalemkerian has studied the cellular and molecular effects of retinoids and other natural products in small cell lung cancer. He has also designed clinical trials based on his laboratory findings. He has a number of clinical trials available for patients with mesothelioma and lung cancer. Additionally, Dr. Kalemkerian is coordinating the development of a lung cancer research program with an emphasis on experimental therapeutics. His other research interests include the epidemiology of lung cancer, with a focus on the effects of age, race, gender, and treatment on patient outcome. Additionally, Dr. Kalemkerian directs the University of Michigan Multidisciplinary Thoracic Oncology Conference.

Dr. Kalemkerian received his Medical Degree (M.D.) from Northwestern University in Chicago, Illinois, in 1985. From 1985-1989 he completed his Residency at Northwestern University. Dr. Kalemkerian completed his Fellowship in Medical Oncology in 1992 at Johns Hopkins University and he received his Board Certification in Internal Medicine in 1998 and his Board Certification in Medical Oncology in 1991. He was appointed to Clinical Associate Professor position on April 13, 1999. Dr. Kalemkerian received his Recertification in Medical Oncology in 2001.

Dr. Kalemkerian is an active member of several groups, organizations, and societies. He is a member of the cooperative group Radiation Therapy Oncology Group (DTOG) and the Southwest Oncology Group (SOG). He is also a member of the American Society of Clinical Oncology (ASCO).

In addition to his active memberships and current positions, Dr. Kalemkerian also has numerous publication credits. The following are just a few of Dr. Kalemkerian’s Peer-Reviewed publications.

Phase II study of celecoxib and docetaxel in non-small cell lung cancer patients with progression after platinum-based therapy. Proc ASCO 22:684; 2003.

Impact of gender in lung cancer – analysis of the national SEER database. 4th International Lung Cancer Congress, Abstract # 17, 2003

Phase II study of fenretinide in patients with small cell lung cancer with progression after first- or second-line chemotherapy. Lung Cancer 41(suppl 2):S234, 2003.

Impact of gender in lung cancer – analysis of the national SEER database. Lung Cancer 41(suppl 2):S113-S114, 2003.